[In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast]
- PMID: 16083587
[In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast]
Abstract
Objective: To study the effect of combination rhOPG-Fc and alendronate on mature osteoclasts.
Methods: Recombinant human osteoprotegerin secretory expression in P. pastoris was performed. Osteoblasts were got from new born mouse skeletal bone and proved by ALP staining and incubated together with osteoclasts precursor cell line Raw 264.7 in 96 well plate. After 9 d, 10 micromol/L ALN, 10(-5) g/L rhOPG-Fc, 10 micromol/L ALN + 10(-5) g/L rhOPG-Fc, 5 micromol/L ALN + 5 x 10(-6) g/L rhOPG-Fc were added to these coculture systems. Osteoblasts cultured without the drugs mentioned above served as controls. TRAP stain positive cells counting and cortical bone pit formation counting were preformed in the following the 3rd and 7th d.
Results: SDS-PAGE and Western blot showed that molecular weight of the expressed protein was about 55 KD, and it could reach specifically with anti-IgG antibody. Many multi-nuclear TRAP stain positive cells were found in the coculture control group after 9 d incubation, and proved to be mature osteoclasts by TRAP stain. In the 3rd and 7th d after the addition of rhOPG-Fc, ALN or both, TRAP stain positive cells counting and cortical bone pit formation counting decreased significantly in the rhOPG-Fc, ALN or both groups than in the control group, and the combine group (10(-5) g/L rhOPG-Fc + 10 micromol/L ALN) decreased most significantly when compared with rhopG-FC or ALN single.
Conclusions: rhOPG-Fc can decrease the number of osteoclasts and inhibit their function. The combination of both rhOPG-Fc and ALN shows the significant inhibition effect on mature osteoclasts.
Similar articles
-
[Effects of recombinant human osteoprotegerin and recombinant RANK protein on the differentiation of osteoclast precursors].Zhongguo Gu Shang. 2013 Apr;26(4):324-7. Zhongguo Gu Shang. 2013. PMID: 23844495 Chinese.
-
[Effect of recombinant human osteoprotegerin on osteoclasts stimulated by polyethylene particles].Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2008 Aug;22(8):979-83. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2008. PMID: 18773818 Chinese.
-
Recombinant receptor activator of nuclear factor κB exhibits more marked inhibitory effects on osteoclasts compared with recombinant osteoprotegerin in vitro and in vivo.Mol Med Rep. 2015 Jul;12(1):631-8. doi: 10.3892/mmr.2015.3407. Epub 2015 Mar 3. Mol Med Rep. 2015. PMID: 25738879
-
Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.Arthritis Rheum. 2005 Sep;52(9):2708-18. doi: 10.1002/art.21236. Arthritis Rheum. 2005. PMID: 16142752
-
Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.Bone. 2007 Aug;41(2):165-74. doi: 10.1016/j.bone.2007.04.190. Epub 2007 May 5. Bone. 2007. PMID: 17560185
Cited by
-
Effect of recombinant human bone morphogenetic protein-2 and osteoprotegerin-Fc in MC3T3-E1 cells.J Rheum Dis. 2024 Apr 1;31(2):79-85. doi: 10.4078/jrd.2023.0043. Epub 2024 Feb 1. J Rheum Dis. 2024. PMID: 38559798 Free PMC article.
-
Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats.J Orthop Surg Res. 2011 Jul 13;6:34. doi: 10.1186/1749-799X-6-34. J Orthop Surg Res. 2011. PMID: 21752290 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources